**FOI Ref: 6463**

**Category(ies): Clinical - Drugs**

**Subject: Antifungal Treatment**

**Date Received: 27/06/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I would be grateful if you would please answer the following questions concerning antifungal treatment within your organisation. |
| 1. What is the number of patients in the last 12 months treated with the following product lines?
2. anidulafungin
3. caspofungin
4. micafungin
 | a. 51b. 17c. 0 |
| 1. What is the split of indication over the last 12 months for the following product lines?
2. anidulafungin
3. caspofungin
4. micafungin
 | * 17 Candida,
* 12 fungal suspected/empirical,
* 4 microbiology recommended,
* 2 intra-abdominal sepis,
* 1 small bowel leak,
* 1 pneumomediastinium,
* 6 yeast in blood culture,
* 1 oesophageal perforation,
* 3 sepsis,
* 2 perforation,
* 1 upper GI perforation,
* 1 yeast in nephrostomy tube,
* 1 pancreatic collection
* 2 fungal cover for chest,
* 5 fungal infection,
* 1 aspergillosis,
* 1 chemo antifungal prophylaxis,
* 1 aml refractory fever,
* 2 neutropenic sepsis,
* 1 MDS,
* 2 candida,
* 1 aml prophylaxis,
* 1 aml chest sepsis,
* 1 copious oral secretions,
* 1 oesophageal perf
1. Don’t do
 |
| 1. For each of the indication splits of the 3 product lines mentioned previously (anidulafungin, caspofungin and micafungin from Q2) list the average length of treatment time.
 | Anidulafungin = 8.5 daysCaspofungin = 8.6 daysMicafungin = 0 |